Antihypertensive drugs in combination: Additive or greater than additive?

Journal of Human Hypertension

Volumn 21, Issue 12, 2007, Pages 914-916

  McInnes, G T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LERCANIDIPINE; PERINDOPRIL; PLACEBO; RENIN;

ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG POTENTIATION; DRUG RESPONSE; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; NOTE; PERIPHERAL EDEMA; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 36448934129     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002272     Document Type: Note

References (20)

1. Puig JG, Calvo C, Luurila O, Luurila H, Sulosaari S, Strandberg A et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: Placebo controlled, randomised, crossover study with 4 ABPM. J Human Hypertens 2007; 21: 917-924 (this issue).
2. Primatesta P, Poulter NR. Improvement in hypertension management in England: Results from the Health Survey of England 2003. J Hypertens 2006; 24: 1187-1192.
3. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 2004; 43 10-17.
4. Chobanian AV, Bakris GE, Black HR, Cushman WC, Green LA, Izzo JL et al., The National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure. The JNC7 report. JAMA 2003; 289: 2560-2572.
5. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462-1536.
6. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185.
7. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Comparative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
8. Lip GY, Barnett AH, Bradbury A, Cappuccio FP, Gill PS, Hughes E et al. Ethnicity and cardiovascular disease prevention in the United Kingdom: A practical approach to management. J Hum Hypertens 2007; 21(3): 183-211.
9. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS-Y, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2000; 20: 771-777.
10. ALLHAT Officers and co-ordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 327: 1427-1435.
12. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med 1994; 154: 1430-1431.
13. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation, of four major classes. Lancet 1999; 353: 2008-2013.
14. Marshall T. How many antihypertensives do patients need to achieve a target blood pressure? J Hum Hypertens 2005; 19: 317-319.
15. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/ hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20(3): 177-185.
16. Rump LC, Ambrosioni E, Burnier M, Horl W, Rabelink AJ. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006; 20 4): 299-301.
17. Ragot S, Sosner P, Yau C, Brunel P, Herpin D. Management in general practice of hypertensive patients poorly controlled with a fixed-dose renin-angiotensin system inhibitor and diuretic combination: Results from a French national survey. J Hum Hypertens 2006; 20(6): 407-418.
18. Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs 1994; 48: 16-24.
19. Dahlõf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
20. Brunner HR, Méndard J, Waeber B, Burnier M, Biollaz J, Nussberger J et al. Treating the individual patient: Considerations of dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3-11.